Trends in Neurosciences
ReviewNon-competitive antagonists of excitatory amino acid receptors
References (45)
- et al.
Neuropharmacology
(1985) - et al.
Neurosci. Lett.
(1985) - et al.
Trends Pharmacol. Sci.
(1986) - et al.
Eur. J. Pharmacol.
(1986) - et al.
Eur. J. Pharmacol.
(1982) Brain Res.
(1975)- et al.
Brain Res.
(1984) - et al.
Brain. Res.
(1986) - et al.
Brain Res.
(1986) - et al.
FEBS Lett.
(1985)
Neurosci. Lett.
Br. J. Pharmacol.
Br. J. Pharmacol.
Eur. J. Pharmacol.
Br. J. Pharmacol.
Science
Mol. Pharmacol.
Cited by (490)
Recent Applications of Selected Name Reactions in the Total Synthesis of Alkaloids
2021, Recent Applications of Selected Name Reactions in the Total Synthesis of AlkaloidsGeneral and Catalytic Enantioselective Approach to Isopavine Alkaloids
2017, Journal of Organic ChemistryNBQX, a highly selective competitive antagonist of AMPA and KA ionotropic glutamate receptors, increases seizures and mortality following picornavirus infection
2016, Experimental NeurologyCitation Excerpt :This result supports the suggestion that the action of NBQX (AMPA/KA receptor antagonist) is through the KA receptors as opposed to the AMPA receptors in the TMEV-induce seizure model. MK 801 has been shown to be an antagonist of the NMDA receptor ion channel (Kemp et al., 1987; Wong et al., 1986). MK 801 treatment was found to protect hippocampal neurons against ischemic neuronal necrosis in the rat (Rod and Auer, 1989), and to protect hippocampal CA1 and CA3 neurons against damage in a rat model of mTLE (KA-induced SE), however no antiepileptogenic effects were evident when MK 801 was administered after KA-induced SE (Brandt et al., 2003).
NMDA receptor subtypes: Structure, function and therapeutics
2008, Current Anaesthesia and Critical CareApnea promotes glutamate-induced excitotoxicity in hippocampal neurons
2007, Brain ResearchCitation Excerpt :Thereafter, there was a lack of potentiation of the fEPSP throughout the period of apnea as shown in Fig. 2A. In another animal, MK-801 was injected intravenously in order to assess the global effects of the blockade of NMDA receptors, since the drug passes through the blood–brain barrier (Kemp et al., 1987). After the injection of MK-801 (2 mg/kg in saline, i.v.) 15 min prior to the induction of apnea, there was no change in the amplitude of the fEPSP and apnea was no longer able to produce any potentiation of the fEPSP (data not shown).
Protective use of N-methyl-D-aspartate receptor antagonists as a spinoplegia against excitatory amino acid neurotoxicity
2005, Journal of Vascular Surgery